(Q40639970)

22 September 2017

title

Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines (English)

1 reference

22 September 2017

3

W Martin Kast

1 reference

22 September 2017

Diane M Da Silva

1

1 reference

22 September 2017

John T Schiller

series ordinal

2

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

22 September 2017

1 reference

22 September 2017

volume

21

1 reference

22 September 2017

issue

23

1 reference

22 September 2017

page(s)

3219-3227

1 reference

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

A controlled trial of a human papillomavirus type 16 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Viral vectors for gene transfer: a review of their use in the treatment of human diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Immunization of mice with HPV vaccinia virus recombinants generates serum IgG, IgM, and mucosal IgA antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Characterization of a major neutralizing epitope on human papillomavirus type 16 L1

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Chimeric papillomavirus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Natural history of cervicovaginal papillomavirus infection in young women.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Seroprevalence of human papillomavirus type 16 infection in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRB interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Immunological analyses of human papillomavirus capsids

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

A formalin-inactivated vaccine protects against mucosal papillomavirus infection: a canine model

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Healthy skin of many animal species harbors papillomaviruses which are closely related to their human counterparts

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

The prime-boost strategy: exciting prospects for improved vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900237-8

7 January 2021

10.1016/S0264-410X(03)00237-8

Identifiers

DOI

1 reference

22 September 2017

1 reference